Uniqure
uniQure NV is a Dutch gene therapy pioneer developing adeno-associated virus (AAV) based gene therapies for severe genetic disorders. The company developed Hemgenix, the first FDA-approved gene therapy for hemophilia B, commercialized with CSL Behring, while advancing clinical programs for Huntington's disease, Fabry disease, and temporal lobe epilepsy. Principal revenues derive from commercial product sales royalties, manufacturing milestone payments, and research partnership licensing fees. Core end markets encompass specialized medical centers, hematology and neurology hospital clinics, and prescription patients across North America and Europe. uniQure holds a pioneer market-leading position in commercial-scale AAV gene therapy development and manufacturing. The company is incorporated in the Netherlands, headquartered in Amsterdam and Lexington, Massachusetts, with ordinary shares traded on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Uniqure.
- Legal name
- Uniqure NV
- Sector
- Health Care
- Country
- Netherlands
- Funds holding it
- 5
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Uniqure
- JPM US Small Cap Growth Fund — JPM · 0.88 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.18 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)